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Cryptosporidium parvum is an important human
pathogen and potential bioterrorism agent. No vac-
cines exist againstC. parvum, the drugs currently ap-
proved to treat cryptosporidiosis are ineffective, and
drug discovery is challenging because the parasite
cannot be maintained continuously in cell culture.
Mining the sequence of the C. parvum genome has
revealed that the only route to guanine nucleotides
is via inosine-50-monophosphate dehydrogenase
(IMPDH). Moreover, phylogenetic analysis suggests
that the IMPDH gene was obtained from bacteria by
lateral gene transfer. Here we exploit the unexpected
evolutionary divergence of parasite and host en-
zymes by designing a high-throughput screen to
target the most diverged portion of the IMPDH ac-
tive site. We have identified four parasite-selective
IMPDH inhibitors that display antiparasitic activity
with greater potency than paromomycin, the current
gold standard for anticryptosporidial activity.INTRODUCTION
The ‘‘vicious cycle of diarrhea and malnutrition’’ in developing
countries could be broken with the advent of effective chemo-
therapy against Cryptosporidium parvum (Berkman et al.,
2002; Huang et al., 2004; Huang and White, 2006). C. parvum
is also an important pathogen in the developed world, where
AIDS patients are at risk of severe infection (Carey et al., 2004;
Fayer, 2004). The parasite produces spore-like oocysts that
are resistant to common methods of water treatment, so Crypto-
sporidium also poses a credible bioterrorism threat (DuPont
et al., 1995). The tools to respond to such an incident are woe-
fully inadequate: no vaccines or effective drug treatments are
currently available. The damage would be substantial: the eco-
nomic cost of the 1993 Milwaukee outbreak, where 400,000
individuals contracted disease, totaled $31.7 million in medical
costs and another $64.6 million in productivity losses (Corso
et al., 2003). Independent of such bioterrorism scenarios, effec-70 Chemistry & Biology 15, 70–77, January 2008 ª2008 Elsevier Ltdtive drugs are urgently needed for the management of crypto-
sporidiosis in AIDS patients and epidemic outbreaks.
The search for drugs to treat cryptosporidiosis has been almost
futile. Compounds such as spiramycin, clarithromycin, paromo-
mycin, and nitazoxanide display modest activity in model systems
but limited efficacy in clinical trials with immunocompetent pa-
tients and poorefficacy in immunocompromised patients (Abuba-
kar et al., 2007; Mead, 2002). Commonly used antiparasitic drugs
fail againstC.parvum, which is not surprising given that theC.par-
vum genome has undergone massive gene loss and horizontal
transfer when compared with related apicomplexan parasites
such as Plasmodium and Toxoplasma (Abrahamsen et al., 2004;
Striepen et al., 2004; Templeton et al., 2004; Xu et al., 2004).
C. parvum cannot be maintained in continuous cell culture and
genetic tools do not exist, so the validation of new drug targets
is thwarted by a dearth of information about parasite metabolism.
Nevertheless, the C. parvum genome has revealed the presence
of a very streamlined purine salvage pathway that relies on the up-
take of adenosine (Abrahamsen et al., 2004; Striepen et al., 2004;
Xu et al., 2004). The only route to guanine nucleotides is via
IMPDH, which catalyzes the conversion of IMP to XMP with the
concomitant reduction in NAD+ (Figure 1A). Phylogenetic analysis
suggests that C. parvum IMPDH was obtained from a bacterial
source by lateral gene transfer (Striepen et al., 2002, 2004), and
C. parvum IMPDH is only 39% identical to the human isozymes
IMPDH1 and IMPDH2. Whereas the IMP site is conserved, the
NAD site is highly diverged and several inhibitors, most notably
mycophenolic acid, bind selectively to the NAD site of human
IMPDHs (Ratcliffe, 2006). Thus, the NAD site is themostpromising
target for parasite-selective inhibitors (Figure 1B).
Here we devise a screen to target the NAD site of C. parvum
IMPDH and identify ten parasite-selective inhibitors with values
of IC50 ranging from 0.1 to 20 mM. The best inhibitors display anti-
parasitic activity in a cell-culture model of infection. To our knowl-
edge, these compounds are the first parasite-specific IMPDH
inhibitors and the first target-based antibiotics for C. parvum.
RESULTS AND DISCUSSION
High-Throughput Screening
We devised an HTS to identify inhibitors that target the NAD+ site
of C. parvum IMPDH, taking advantage of a detailed knowledgeAll rights reserved
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Inhibition of C. parvum IMPDHof the kinetic mechanism which allows us to calculate the distri-
bution of enzyme-substrate complexes at various substrate con-
centrations (Figure 1C; see Table S1 in the Supplemental Data
available with this article online) (Digits and Hedstrom, 1999;
Umejiego et al., 2004; T.V.R., W. Wang, H. Josephine, and
L.H., unpublished data). We chose high IMP concentrations
(250 mM) so that IMP binds first. Under these conditions, only
0.4% of the enzyme is in the E state and less than 0.7% will
be present as ENAD+, so the IMP site is virtually inaccessible
to inhibitors; only compounds with low nanomolar affinities for
the IMP site would be identified in this screen. NAD+ binds sec-
ond and hydride transfer is rapid to form the covalent intermedi-
ate E-XMP* and NADH. NADH then departs and a mobile flap
folds into the vacant site, forming the closed conformation re-
quired for the hydrolysis of E-XMP* (Hedstrom and Gan, 2006).
We chose an NAD+ concentration (500 mM) high enough to gen-
erate a robust signal in the HTS, but low enough that significant
fractions of the EIMP and E-XMP*open complexes are present
(7% and 11%, respectively). Therefore, HTS should yield micro-
molar inhibitors that bind to the highly diverged NAD site. The
HTS protocol is summarized in Table S2 and the results for a
typical plate are shown in Figure S1.
This screen identified 134 compounds that inhibitedC. parvum
IMPDH by at least 45% (z scores% 10; hit rate of 0.3%). Eigh-
teen of these compounds inhibited C. parvum IMPDH in the sec-
ondary screen, and 11 of these 18 compounds did not inhibit
human IMPDH2. Authentic samples of these compounds were
purchased or synthesized, and compound structure and purity
were confirmed by NMR and mass spectroscopy (see the Sup-Chemistry & Biologyplemental Data for details on synthesis). One of the authentic
samples did not inhibitC. parvum IMPDH. The remaining 10 com-
pounds were characterized further (compounds A–K; Table 1).
Characterization of the Principal Hits
The values of IC50 for these compounds range from 0.13 to
19 mM, with only compound K in excess of 10 mM. In all cases,
the inhibition data are well described by a simple binding func-
tion (Equation S1) which indicates that the compounds are re-
versible inhibitors (Figure 2A). Selectivity ranges from R9-fold
higher affinity for the parasite enzyme in the worst case (J) to
more than 400-fold (G) (Table 1).
The Mechanism of Inhibition
All of the compounds are uncompetitive inhibitors with respect to
IMP and noncompetitive (mixed) with respect to NAD+ (Figures
2B and 2C), indicating that the inhibitors bind to both EIMP
and E-XMP*open as designed. Most of the compounds display
similar affinities for both complexes, butD and J display a prefer-
ence for EIMP (Table 2). To further localize the site of inhibitor
binding within the NAD site, we analyzed how the compounds
interact with tiazofurin, which binds in the nicotinamide subsite
(Hedstrom et al., 1990). Typical dual-inhibitor experiments are
shown in Figures 2D–2F. If two inhibitors are mutually exclusive,
a parallel line pattern is observed (Figure 2D), and a, the interac-
tion constant, is infinity (N). The binding of tiazofurin is mutually
exclusive with all of the inhibitors, indicating that all bind in the
nicotinamide subsite (G is too potent and K is too weak to permit
this analysis). However, none of the inhibitors block ADP bindingFigure 1. Mechanism and Structure of IMPDH
(A) The IMPDH reaction.
(B) The active site, rendered by sequence conservation. The structure of EIMPtiazofurin adenine dinucleotide complex of IMPDH from Tritrichomonas fetus
(Protein Data Bank ID code 1LRT). The image was produced using the UCSF Chimera package (Pettersen et al., 2004). The percentage of sequence identity
is colored as shown using the alignment from Striepen et al. (2002). TZ, tiazofurin; Ado, adenosine.
(C) The kinetic mechanism of IMPDH, showing the distribution of enzyme under the conditions of the HTS (250 mM IMP and 500 mM NAD+), determined as
described in the Supplemental Data. Not shown: ENAD+% 0.7%, E-XMP*NAD+ = 1%.15, 70–77, January 2008 ª2008 Elsevier Ltd All rights reserved 71
Table 1. Charac
Inhibitor Cp/H2
% Cp
Growth
Inhibition
(SD)
Cytotoxicity
(SD)
Cytostatic
Effects
A R35 32 (1)RT n.d. 
B R400 83 (2)RT 15 (5) 
C R50 91 (1)RT 4 (2) 
D R9 8 (20) 7 (3) +
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dterization of the Parasite-Selective Inhibitors
IMPDH IC50 (mM)
Cp/H2
% Cp
Growth
Inhibition
(SD)
Cytotoxicity
(SD)
Cytostatic
Effects Inhibitor
IMPDH IC50 (mM)
Cp H1a H2b Cp H1a H2b
3.3 ± 0.2 >50 >50 R15 70 (4)RT 2 (6) + F 1.4 ± 0.1 >50 >50
1.6 ± 0.2 >50 >50 R30 24 (9) 49 (2)  G (n = 1) 0.13 ± 0.02 >50 >50
1.2 ± 0.2 >50 >50 R40 30 (10) n.d.  H (n = 2) 0.9 ± 0.1 >50 >50
5.4 ± 0.2 >50 >50 R10 31 (9) n.d.  J 5.9 ± 0.7 >50 >50
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Chemistry & Biology(Figures 2E and 2F; Table 2), which is somewhat surprising, as
the adenosine subsite is the most different from the host enzyme
(Figure 1B). Compounds B, C, D, H, and J interact either syner-
gistically or independently with ADP (a% 1), which indicates that
the binding site for these inhibitors does not extend into the ADP
subsite. In contrast, the binding of A, E, and F antagonizes ADP
binding (a R 1), indicating that the binding site for these com-
pounds impinges on the ADP site, either directly or by inducing
a conformation that decreases the affinity for ADP. Compounds
A, E, and F are not significantly larger than the other inhibitors,
which suggests that these compounds have an alternative bind-
ing mode. Thus, the screen has identified two classes of para-
site-selective inhibitors.
Antiparasitic Activity in Cell-Culture Model
of Parasite Growth
We next assessed whether the inhibitors have antiparasitic ac-
tivity. C. parvum is an obligate intracellular parasite that cannot
be maintained in continuous cell culture. However, sporozoites
readily infect a variety of epithelial cells, undergoing the first
two asexual replication cycles. Even though the life cycle is in-
complete, these in vitro infections are sufficient for an initial eval-
uation of antiparasitic activity (Arrowood, 2002; Upton, 1997).
Because parasite and host cell metabolism are intertwined, we
first assessed the cytotoxic and cytostatic effects on human ileo-
cecal adenocarcinoma epithelial HCT-8 cells, a widely used host
cell model. Only compound B displayed significant cytotoxic
effects in a lactate dehydrogenase (LDH) release assay; G and
H are mildly cytotoxic, whereas A, J, andK are slightly cytostatic
(Table 1; Figure 3A).
HCT-8 cells were infected with oocysts of C. parvum Iowa iso-
late and parasites proliferated 15-fold over 48 hr as measured
by quantitative real-time PCR (Figure 3B). Parasites were also
quantified using a biotin-conjugated VVL lectin that specifically
recognizes sporozoites and intracellular stages but not the outer
oocyst wall (see Experimental Procedures) (Gut and Nelson,
1999b; Hashim et al., 2004, 2006; Winter et al., 2000). Paromo-
mycin inhibited parasite growth with a value of EC50 = 120 mM,
validating the assay (literature values of EC50 = 65–130 mM;
Perkins et al., 1998; Woods et al., 1995; You et al., 1996) (Fig-
ure S2). Compounds A, F, G, and H display significant dose-de-
pendent antiparasitic activity in this assay (Table 1; Figure 3C).
We confirmed the antiparasitic activity of A, F, G, and H using
a real-time PCR assay that measures the abundance of parasite
ribosomal RNA genes (Figure 3D) (Cai et al., 2005). No correla-
tion exists between the antiparasitic activity of the compounds
and cytotoxic/cytostatic effects, so the antiparasitic activities
must result from direct effects on the parasite. These observa-
tions suggest that at least four compounds (A, F, G, and H) enter
the parasite, which is a very important finding given that failure of
drug uptake has been frequently invoked to explain the resis-
tance of Cryptosporidium to antiparasitic drugs (Griffiths et al.,
1998; Mead, 2002).
SIGNIFICANCE
C. parvum is an important pathogen of both the developed
and developing world and a potential biowarfare agent.
This protozoan parasite has eluded drug treatment and noT
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Inhibition of C. parvum IMPDHvaccines exist. Eukaryotic pathogens present a particularly
challenging problem for drug design because the targets
generally bear a close resemblance to host proteins. Surpris-
ingly, the purine salvage pathway of C. parvum relies on an
IMPDH likely obtained from a prokaryote through horizontal
gene transfer, and thus is very different from the host coun-
terpart (Striepen et al., 2002, 2004). We designed an HTS to
target the highly divergedNAD site by exploiting our detailed74 Chemistry & Biology 15, 70–77, January 2008 ª2008 Elsevier Ltdunderstanding of the kinetic mechanism of C. parvum
IMPDH. This screen identified ten parasite-selective inhibi-
tors, all ofwhich bind in theNADsite as designed. Twodiffer-
ent classes of interactions are observed: five compounds
bindonly in thenicotinamideportionof theNADsite,whereas
three extend from the nicotinamide site into the adenosine
subsite. Four compounds display antiparasitic activity in
a cell-culturemodel of infection, further validating the choiceFigure 2. Inhibitor Characterization
(A) IC50 determination for compound F.
(B) The mechanism of inhibition for compound F versus IMP, [F] = 0.0 mM;; 0.5 mM;: 1.0 mM;- 2.5 mM;A 5.0 mM.
(C) The mechanism of inhibition for compound F versus NAD+, [F] =C 0.0 mM;A 0.5 mM;; 1.0 mM;: 2.5 mM;- 5.0 mM.
(D) Dual-inhibitor experiments for compound F versus tiazofurin, [tiazofurin] =C 0.0 mM;; 2.0 mM;- 4.0 mM;A 6.0 mM;: 8.0 mM.
(E) Dual-inhibitor experiments for compound F versus ADP, [ADP] =C 0.0 mM;; 5.0 mM;- 10.0 mM;A 15.0 mM;: 20.0 mM.
(F) Dual-inhibitor experiments for compound H versus ADP, [ADP] =C 0.0 mM;; 5.0 mM;- 10.0 mM;A15.0 mM;: 20.0 mM.
Conditions as described in Experimental Procedures.Table 2. Mechanism of Inhibition
Inhibitor
Versus IMP (UC) Versus NAD+ (NC) Dual-Inhibitor Analysis a
Kii (mM) EIMP Kis (mM) E-XMP* Kii (mM) Tiazofurin ADP
A 5.6 ± 0.5 3 ± 2 4 ± 2 N (ME) 1.3 (I)
B 2.7 ± 0.2 1.7 ± 0.6 2.5 ± 1.2 N (ME) 0.6 (S)
C 1.5 ± 0.1 1.5 ± 0.7 1.4 ± 0.2 N (ME) 0.3 (S)
D 4.5 ± 0.4 1.8 ± 0.5 7 ± 4 N (ME) 0.7 (S)
E 1.0 ± 0.1 4.1 ± 2.0 1.5 ± 0.3 N (ME) 2.7 (A)
F 3.7 ± 0.4 1.4 ± 0.2 2.7 ± 0.6 N (ME) 2.0 (A)
G 0.17 ± 0.01 0.14 ± 0.04 0.20 ± 0.05 n.d. n.d.
H 0.61 ± 0.02 1.3 ± 0.4 1.1 ± 0.4 N (ME) 0.8 (I)
J 11.4 ± 0.3 4.1 ± 0.2 15 ± 3 N (ME) 0.6 (S)
Nomenclature of Cleland (1963), where noncompetitive (mixed) inhibition is described by two inhibition constants, Kis and Kii. In the present case, Kis
and Kii describe the affinity of the inhibitor for the EIMP and E-XMP* complexes, respectively. UC, uncompetitive; NC, noncompetitive; ME, mutually
exclusive; I, independent; S, synergistic; A, antagonistic. n.d., not determined.All rights reserved
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Inhibition of C. parvum IMPDHof IMPDH as target against cryptosporidiosis. Importantly,
our inhibitors are already more potent than paromomycin,
the current gold standard for anticryptosporidial activity.EXPERIMENTAL PROCEDURES
Materials
The compound collections were provided by the National Screening Labora-
tory for the Regional Centers of Excellence in BioDefense and Emerging Infec-
tious Disease (NSRB) at Harvard Medical School. The initial screen included
44,522 compounds from the following libraries: ActiMol TimTec 1, Bionet 2,
ChemDiv 2, ChemDiv 3, Maybridge 4, NINDS custom collection, SpecPlus col-
lection, BIOMOL ICCB known bioactives, ICBG 1 fungal extracts, and Starr
Foundation extracts 1. Compounds D, E, F, G, H, and L were purchased
from ChemDiv (San Diego, CA, USA), K from TimTec (Newark, DE, USA),
and J from Asinex Ltd. (Moscow, Russia). Compounds A, B, and C were syn-
thesized as described in the Supplemental Data. C. parvum oocysts of the
Iowa strain were a kind gift from Dr. J. R. Mead (Emory University). VVL-biotin
was purchased from Vector Labs (Burlingame, CA, USA).Enzyme Purification and Assays
Recombinant human IMPDH1 and IMPDH2 and C. parvum were expressed in
guaB strains of Escherichia coli (which lack endogenous IMPDH) and purified
as described previously (Farazi et al., 1997; Mortimer and Hedstrom, 2005;
Umejiego et al., 2004). Assays were routinely performed in 50 mM Tris-HCl
(pH 8.0), 100 mM KCl, 3 mM EDTA, and 1 mM dithiothreitol (assay buffer) atFigure 3. Activity of the Principal Hits in
a Cell-Culture Model of Cryptosporidium
Infection
(A) Representative cytotoxicity assay showing the
cytolytic effects of compoundsG andHmonitored
by the release of lactate dehydrogenase (LDH).
(B) Parasite proliferation as measured by real-time
PCR over 48 hr, the period over which the antipar-
asitic effects of compounds A–K were deter-
mined.
(C) VVL-ELISA C. parvum growth assay.
(D) Real-time PCR C. parvum growth assay. As-
says as described in Experimental Procedures.
The error bars represent the standard deviation.
Paro, paromomycin.
25C. The production of NADH was monitored
by following changes in absorbance or fluores-
cence.
Primary Screen
Table S2 describes the assay protocol. Assays
were performed in duplicate in 384-well, clear
flat bottom polystyrene nonbinding surface micro-
plates (Corning 3640). Inhibitors (100 nl) were
added to 30 ml of enzyme solution. An initial absor-
bance measurement at 340 nm was obtained us-
ing an Envision plate reader, and the reaction
was initiated by the addition of IMP and NAD (40
ml) to give final assay conditions: 250 mM IMP,
500 mM NAD, and 70 nM C. parvum IMPDH in as-
say buffer. The reaction proceeded for 3 hr, then
was quenched by the addition of GMP (10 ml, final
concentration 25 mM). The absorbance at 340 nm
was measured, and the change in absorbance
was determined by subtracting the initial value.
Positive (12–25 mM GMP) and negative (no inhib-
itor) controls were included on each plate. ThisChemistry & Biologyscreen identified 134 compounds that displayed >45% inhibition with z
scores% 10.
Inhibitor Characterization
The values of Ki with respect to NAD
+ were determined using a saturating IMP
concentration (150 mM; Km = 29 mM; Umejiego et al., 2004) and varied NAD
+
concentrations. The values of Ki with respect to IMP were determined by using
a fixed NAD+ concentration (500 mM; Km = 150 mM; Umejiego et al., 2004). The
mechanism of inhibition was determined by the fit to the appropriate equation
for uncompetitive or noncompetitive inhibition (Cleland, 1963). Dual-inhibition
experiments with tiazofurin and ADP were performed with constant concentra-
tions of IMP (250 mM) and NAD+ (250 mM). Data were fit to an equation describ-
ing multiple inhibition (Equation 1),
n= n0=ð1+ ½I=Ki + ½J=Kj + ½I½J=aKiKjÞ; (1)
where I and J are the inhibitors, n0 is the initial velocity in the absence of inhib-
itors, a is the interaction constant, and Ki and Kj are the inhibition constants of
I and J, respectively. Values of a> 8000 were assigned asN. Detailed protocols
are provided in the Supplemental Data.
Cell-Culture Model of C. parvum Infection
The human ileocecal adenocarcinoma epithelial cell line, HCT-8, was used to
support C. parvum infection in vitro. Oocysts were treated with 10 mM HCl to
facilitate excystation (Gut and Nelson, 1999a) and applied to an HCT-8 mono-
layer. Parasites were measured with biotin-conjugated VVL (Vector Labs,
Burlingame, CA, USA) in a cell-based ELISA adapted to a 96-well format
(Gut and Nelson, 1999b; Moriarty et al., 2005), or by real-time PCR as15, 70–77, January 2008 ª2008 Elsevier Ltd All rights reserved 75
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Inhibition of C. parvum IMPDHdescribed by Cai et al. (2005). Detailed protocols are provided in the Supple-
mental Data.
Effects of the Compounds on the Host Cells
The cytotoxic and cytostatic effects of compounds A–K on HCT-8 cells were
determined using the CytoTox96 assay (Promega, Madison, WI, USA) and the
LIVE/DEAD assay (Molecular Probes, Carlsbad, CA, USA).
Supplemental Data
Supplemental Data include two figures, two tables, Supplemental Experimen-
tal Procedures, and Supplemental References and can be found with this
article online at http://www.chembiol.com/cgi/content/full/15/1/70/DC1/.
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